retatrutide phase 2 nejm 2023 obesity trial jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Phase 2 NEJM Trial:

Jedn z najwikszych barier w dostpie do nowoczesnego leczenia otyoci w Polsce jest brak refundacji przez Narodowy Fundusz Zdrowia (NFZ)

Generics to dramatically cut cost: experts Novo Nordisk the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy had for years held a patent on semaglutide, the active ingredient in those drugs that triggers the release of insulin and is used to treat diabetes and to aid weight loss

Tissue Repair Peptide Body Protection Compound BPC-157 is a synthetic peptide derived from a protective protein in the stomach, known for its remarkable tissue healing properties

Muscle Growth : By helping with muscle repair and recovery, BPC 157 can give you that extra edge to build stronger muscles over time

During that time: 2.35% of people taking GLP-1 drugs developed epilepsy

Some are prescribed off-label by medical providers